menu
    • menu

    Company profile for Merck & Co

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Laboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our goal is to lead the way to a healthier future. But we also care about how we get there together. As a company whose products touch the lives and well being of people around the world, we hold ourselves to a high standard. And we expect others to hold us to that same high standard. We believe in operating openly, honestly and with the highest degree of ethics and integrity. This includes: making sure that the compa...
    Our goal is to lead the way to a healthier future. But we also care about how we get there together. As a company whose products touch the lives and well being of people around the world, we hold ourselves to a high standard. And we expect others to hold us to that same high standard. We believe in operating openly, honestly and with the highest degree of ethics and integrity. This includes: making sure that the company complies with all applicable laws and regulations globally.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Merck & CoUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Merck Drive, P.O. Box 100 Whitehouse Station, NJ 08889-0100
    Telephone
    Telephone
    +1 732 422 7800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.merck.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI Korea

    Not Confirmed

    envelop Contact Supplier

    CPhI Korea

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    "50 Years of Innovation: Mikart

    mic"50 Years of Innovation: Mikart's legacy and what's next in CDMO excellence"

    This week, SpeakPharma interviews Michael Kallelis, CEO of Mikart, a leading contract development and manufacturing organization (CDMO) celebrating its 50th anniversary in the pharmaceutical industry. Based in the United States, Mikart has built a reputation for technical expertise, flexible business terms, and specialized capabilities in pharmaceutical development services. In this exclusive interview, Kallelis discusses how Mikart maintains its competitive edge through its Pharmaceutical Development Services team, quality control framework, and commitment to customized business solutions. Kallelis also explores the company's focus on liquid suspensions manufacturing, driven by growing demand from aging populations and pediatric patients, and explains how Mikart balances traditional family business values with modern innovation. HIGHLIGHTS// celebrating its 50th anniversary/ reputation for technical expertise/ how Mikart maintains its competitive edge Mikart is celebrating 50 years in business this year — what are some of the major milestones that have shaped the company's journey? Over our 50-year history, we've celebrated many memorable milestones, but one of the most significant in recent years has been achieving our growth objectives. This success was driven by the strategic expansion of our Pharmaceutical Development Services team, the completion of full aggregate serialization in our packaging department, modernization of our IT systems, enhanced productivity, and our ability to attract both new and returning customers. HIGHLIGHTS// expansion of our Pharmaceutical Development Services team/ completion of full aggregate serialization/ attract both new and returning customers How has Mikart maintained its competitive edge in a constantly evolving pharmaceutical landscape? Our customers consistently tell us that what sets us apart is our technical expertise, high service level, and flexible, customized business terms. At the core of our competitiveness is our focus on Pharmaceutical Development Services (PDS). Mikart's PDS opinion leaders are actively engaged in business development and form early, collaborative relationships with our customers' technical teams. From the outset, our prospects and clients work directly with Mikart's experienced formulation chemists, analytical method developers, and process-oriented engineers to design robust, reproducible, and efficient processes. This hands-on development approach is supported by a comprehensive quality control testing framework — covering raw material testing, in-process checks, on-site microbiological testing, and in-house stability studies. Oversight is provided by our robust Quality Management System, managed by a dedicated Quality Assurance and Regulatory Affairs team. The result is disciplined problem-solving, timely FDA submissions, and a "right-first-time" philosophy that accelerates time-to-market. We operate with a strong sense of urgency and consistently deliver a high level of customer satisfaction. What truly differentiates Mikart is our commitment to customized business terms that eliminate common roadblocks seen with other CDMOs. Our secret sauce is our exceptional service and flexibility in helping our customers bring innovative medicines to patients. HIGHLIGHTS// technical expertise, high service level/ flexible, customized business terms/ comprehensive quality control testing framework/ dedicated Quality Assurance and Regulatory Affairs team/ timely FDA submissions/ accelerates time-to-market What capabilities or services does Mikart offer today that didn't exist 10 or 20 years ago? Mikart was an early leader in serialization, implementing full capabilities well ahead of the industry timeline. This proactive approach has kept our packaging team in high demand. We also upgraded our tablet compression equipment to enhance both speed and reliability. To support growing development needs, we invested in new lab-scale development equipment, unit dose cup filling, sachet packaging, low-humidity suites, and a brand-new suite dedicated to closed-system manufacturing of liquids and suspensions. Most recently, we launched a multi-million dollar expansion of our packaging lines to support higher-speed tablet filling, powder-in-bottle formats, and new liquid fill capabilities. HIGHLIGHTS// early leader in serialization/ upgraded our tablet compression equipment/ multi-million dollar expansion of our packaging lines Why are liquid suspensions becoming such a key focus, and how is Mikart positioned? Formulating suspensions is a complex process that requires specialized expertise and equipment. According to our customers, few mid-market CDMOs do it well — and Mikart is one of them. There is growing industry demand for high-quality suspension manufacturing, driven by the needs of the aging baby boomer population and pediatric patients. For both groups, swallowing tablets or capsules can be difficult, making oral liquid suspensions a more practical alternative. In addition to being easier to administer, suspensions offer pharmacological advantages and can improve dosing compliance. Enhanced flavoring techniques further improve the patient experience — especially for children and infants — by making medicines more palatable. HIGHLIGHTS// growing industry demand for high-quality suspension manufacturing/ suspensions offer pharmacological advantages/ improve dosing compliance How does Mikart balance tradition with innovation to meet modern customer demands? At Mikart, we work hard to preserve the values of a traditional family business, even as we continue to modernize. Our goal is to make every customer feel like they are our top priority. Each customer is supported by a dedicated project manager who serves as their primary point of contact, along with direct access to key team members across departments. This structure ensures our customers are never isolated from our subject matter experts and can get timely, accurate answers to their questions. We're also mindful of the "technology trap" — the tendency to pursue every new innovation at the expense of focus and efficiency. Instead, we rely on market data and customer trends to guide our investments, enabling us to concentrate our resources and capital on technologies that meet real market needs. HIGHLIGHTS// customer is supported by a dedicated project manager/ customers are never isolated from our subject matter experts/ we rely on market data and customer trends to guide our investments/ meet real market needs Looking ahead, what's in store for Mikart in the next 5-10 years? Mikart's strategic plan is now in full motion, and with the momentum we've built, 50 percent growth is within reach. This projection is backed by a strong pipeline of annual FDA filings, a growing customer base, and a robust portfolio of active Pharmaceutical Development Services projects. As we grow, we remain committed to delivering exceptional service and continuously evolving to meet the changing needs of our customers. With renewed political emphasis on domestic manufacturing for the US market, we are ideally positioned to support the rapid, cost-effective development and production of high-quality medicines here at home. As we approach our 50th anniversary in the CDMO industry, we celebrate our legacy and look forward with optimism to the opportunities ahead in the next 5 to 10 years. HIGHLIGHTS// 50 percent growth is within reach/ strong pipeline of annual FDA filings 

    Impressions: 110

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence

    PharmaCompass
    17 Jul 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaQuality, Reliability, TrustQuality, Reliability, Trust

    Quality, Reliability, Trust
    Quality, Reliability, Trust

    reelQuality, Reliability, Trust

    This PharmaReel highlights Rochem’s capabilities in sourcing and supplying Generic APIs and Excipients, driven by Quality, Reliability, and Trust through fully cGMP-compliant operations. With over 30 years of experience and 16 offices worldwide, Rochem continues to develop partnerships across the US, China, Europe, and South America.

    Impressions: 2104

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4944

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

    #PharmaFlow by PHARMACOMPASS
    10 Jul 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck to Cut 8% of Workforce, Laying Off 6,000
    Merck to Cut 8% of Workforce, Laying Off 6,000

    31 Jul 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/merck-will-lay-6000-3b-annual-cost-cutting-purge

    FIERCE PHARMA
    31 Jul 2025
    Share Share
    Merck Cuts $3 B to Support Aggressive Launch Schedule
    Merck Cuts $3 B to Support Aggressive Launch Schedule

    30 Jul 2025

    // BIOSPACE

    https://www.biospace.com/business/merck-cuts-3b-to-support-aggressive-launch-schedule-late-stage-r-d

    BIOSPACE
    30 Jul 2025
    Share Share
    Merck Axes Main Asset from $1.9 B Pandion Buyout
    Merck Axes Main Asset from $1.9 B Pandion Buyout

    30 Jul 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/merck-axes-midstage-asset-19b-pandion-buyout-due-lack-clinical-benefit

    FIERCE BIOTECH
    30 Jul 2025
    Share Share
    Merck & Co Announces Q2 2025 Financial Results
    Merck & Co Announces Q2 2025 Financial Results

    29 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250729145233/en/Merck-Co.-Inc.-Rahway-N.J.-USA-Announces-Second-Quarter-2025-Financial-Results

    BUSINESSWIRE
    29 Jul 2025
    Share Share
    Merck's Biologics Keytruda Receives Suppl Approval in US
    Merck's Biologics Keytruda Receives Suppl Approval in US

    24 Jul 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514

    FDA
    24 Jul 2025
    Share Share
    Merck Announces Fourth-Quarter 2025 Dividend
    Merck Announces Fourth-Quarter 2025 Dividend

    22 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250722217910/en/Merck-Announces-Fourth-Quarter-2025-Dividend

    BUSINESSWIRE
    22 Jul 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck’s ENFLONSIA Approved for Prevention of RSV Respiratory Tract Disease in Infants

    Details:

    Enflonsia (clesrovimab) an antibody which is approved by USFDA for the treatment of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants.


    Lead Product(s): Clesrovimab

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Enflonsia

    Study Phase: Approved FDFProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 09, 2025

    blank

    01

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clesrovimab

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Merck’s ENFLONSIA Approved for Prevention of RSV Respiratory Tract Disease in Infants

    Details : Enflonsia (clesrovimab) an antibody which is approved by USFDA for the treatment of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants.

    Product Name : Enflonsia

    Product Type : Antibody

    Upfront Cash : Inapplicable

    June 09, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Antengene & MSD Enter into a Global Clinical Collaboration

    Details:

    The collaboration aims to evaluate the combination of ATG-022, a CLDN18.2-targeting ADC, and MSD's anti-PD-1 therapy, Keytruda in patients with advanced solid tumors.


    Lead Product(s): ATG-022,Pembrolizumab

    Therapeutic Area: Oncology Brand Name: ATG-022

    Study Phase: PreclinicalProduct Type: Antibody-drug Conjugate

    Recipient: Antengene

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration May 21, 2025

    blank

    02

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ATG-022,Pembrolizumab

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Recipient : Antengene

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Antengene & MSD Enter into a Global Clinical Collaboration

    Details : The collaboration aims to evaluate the combination of ATG-022, a CLDN18.2-targeting ADC, and MSD's anti-PD-1 therapy, Keytruda in patients with advanced solid tumors.

    Product Name : ATG-022

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Undisclosed

    May 21, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Daiichi’s Phase 3 IDeate-Esophageal01 Trial Starts for Ifinatamab Deruxtecan

    Details:

    I-DXd (ifinatamab deruxtecan) is comprised of a humanized anti-B7-H3 IgG1 monoclonal antibody being investigated for unresectable advanced or metastatic esophageal squamous cell carcinoma.


    Lead Product(s): Ifinatamab deruxtecan

    Therapeutic Area: Oncology Brand Name: I-DXd

    Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate

    Recipient: Daiichi Sankyo

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 19, 2025

    blank

    03

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ifinatamab deruxtecan

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Recipient : Daiichi Sankyo

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Daiichi’s Phase 3 IDeate-Esophageal01 Trial Starts for Ifinatamab Deruxtecan

    Details : I-DXd (ifinatamab deruxtecan) is comprised of a humanized anti-B7-H3 IgG1 monoclonal antibody being investigated for unresectable advanced or metastatic esophageal squamous cell carcinoma.

    Product Name : I-DXd

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    May 19, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck’s KEYNOTE-B96 Hits PFS Goal in PD-L1+ Ovarian Cancer Phase 3 Trial

    Details:

    Keytruda (pembrolizumab), anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1.


    Lead Product(s): Pembrolizumab,Paclitaxel,Bevacizumab

    Therapeutic Area: Oncology Brand Name: Keytruda

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 15, 2025

    blank

    04

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pembrolizumab,Paclitaxel,Bevacizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Merck’s KEYNOTE-B96 Hits PFS Goal in PD-L1+ Ovarian Cancer Phase 3 Trial

    Details : Keytruda (pembrolizumab), anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1.

    Product Name : Keytruda

    Product Type : Antibody

    Upfront Cash : Inapplicable

    May 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Clears Merck’s WELIREG for Adults and Teens with Advanced PPGL

    Details:

    Welireg (belzutifan) is first and only HIF-2α inhibitor, being investigated for the treatment of 12 years and older with advanced, unresectable pheochromocytoma and paraganglioma (PPGL).


    Lead Product(s): Belzutifan

    Therapeutic Area: Oncology Brand Name: Welireg

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 14, 2025

    blank

    05

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Belzutifan

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FDA Clears Merck’s WELIREG for Adults and Teens with Advanced PPGL

    Details : Welireg (belzutifan) is first and only HIF-2α inhibitor, being investigated for the treatment of 12 years and older with advanced, unresectable pheochromocytoma and paraganglioma (PPGL).

    Product Name : Welireg

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    May 14, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck Links up with Cyprumed in $493M Oral Peptide Deal

    Details:

    Under the licensing agreement, MSD will acquire global rights to Cyprumed's platform for developing oral formulations of its peptide therapies.


    Lead Product(s): Undisclosed

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Peptide

    Recipient: Cyprumed

    Deal Size: $493.0 million Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement April 15, 2025

    blank

    06

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Undisclosed

    Recipient : Cyprumed

    Deal Size : $493.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Merck Links up with Cyprumed in $493M Oral Peptide Deal

    Details : Under the licensing agreement, MSD will acquire global rights to Cyprumed's platform for developing oral formulations of its peptide therapies.

    Product Name : Undisclosed

    Product Type : Peptide

    Upfront Cash : Undisclosed

    April 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Organon Acquires Tofidenc, A Commercialized Biosimilar to Actemr in U.S

    Details:

    Through this acquisition, Organon enhances and broadens its U.S. biosimilars portfolio, gaining commercial rights in the US for tofidence (tocilizumab), an intravenous biosimilar to actemra.


    Lead Product(s): Tocilizumab

    Therapeutic Area: Immunology Brand Name: Tofidence

    Study Phase: Approved FDFProduct Type: Antibody

    Recipient: Biogen

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition April 01, 2025

    blank

    07

    Organon

    U.S.A
    arrow
    AGGSpend
    Not Confirmed

    Organon

    U.S.A
    arrow
    AGGSpend
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tocilizumab

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Recipient : Biogen

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Organon Acquires Tofidenc, A Commercialized Biosimilar to Actemr in U.S

    Details : Through this acquisition, Organon enhances and broadens its U.S. biosimilars portfolio, gaining commercial rights in the US for tofidence (tocilizumab), an intravenous biosimilar to actemra.

    Product Name : Tofidence

    Product Type : Antibody

    Upfront Cash : Undisclosed

    April 01, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Enhertu Initiated in Patients with Previously Untreated HER2 Positive Gastric Cancer

    Details:

    Enhertu (trastuzumab deruxtecan) in combination with fluoropyrimidine chemotherapy, pembrolizumab is being studied for unresectable, locally advanced or metastatic HER2 positive gastric or GEJ cancer.


    Lead Product(s): Trastuzumab Deruxtecan,Cisplatin,Pembrolizumab

    Therapeutic Area: Oncology Brand Name: Enhertu

    Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate

    Recipient: Daiichi Sankyo

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 31, 2025

    blank

    08

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trastuzumab Deruxtecan,Cisplatin,Pembrolizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Recipient : Daiichi Sankyo

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Enhertu Initiated in Patients with Previously Untreated HER2 Positive Gastric Cancer

    Details : Enhertu (trastuzumab deruxtecan) in combination with fluoropyrimidine chemotherapy, pembrolizumab is being studied for unresectable, locally advanced or metastatic HER2 positive gastric or GEJ cancer.

    Product Name : Enhertu

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    March 31, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    EU Approves Merck's Capvaxive for Invasive Pneumococcal Disease Prevention

    Details:

    Capvaxive (21-valent Pneumococcal Conjugate Vaccine) is a prophylactic vaccine candidate which is approved for the treatment of pneumococcal pneumonia in adults.


    Lead Product(s): 21-valent Pneumococcal Conjugate Vaccine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Capvaxive

    Study Phase: Approved FDFProduct Type: Vaccine

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 27, 2025

    blank

    09

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 21-valent Pneumococcal Conjugate Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    EU Approves Merck's Capvaxive for Invasive Pneumococcal Disease Prevention

    Details : Capvaxive (21-valent Pneumococcal Conjugate Vaccine) is a prophylactic vaccine candidate which is approved for the treatment of pneumococcal pneumonia in adults.

    Product Name : Capvaxive

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    March 27, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck’s DOR/ISL Two-Drug Regimen Shows 48-Week HIV-1 Viral Suppression in Trials

    Details:

    MK-8591A is a combination of islatravir and Doravirine which are being investigated as non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.


    Lead Product(s): Islatravir,Doravirine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: MK-8591A

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 12, 2025

    blank

    10

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    AGGSpend
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Islatravir,Doravirine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Merck’s DOR/ISL Two-Drug Regimen Shows 48-Week HIV-1 Viral Suppression in Trials

    Details : MK-8591A is a combination of islatravir and Doravirine which are being investigated as non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.

    Product Name : MK-8591A

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    March 12, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Upload your portfolio for free, ask us

    API & Drug Product Development

    Click here to discover the service providers for API & Drug Product Development

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Merck & Co and get a quotation

    Merck & Co is a supplier offers 147 products (APIs, Excipients or Intermediates).

    Find a price of Betamethasone bulk with DMF, CEP offered by Merck & Co

    Find a price of Betamethasone bulk with CEP offered by Merck & Co

    Find a price of Ivermectin bulk with CEP offered by Merck & Co

    Find a price of Loratadine bulk with CEP offered by Merck & Co

    Find a price of 2-Methoxyestradiol bulk offered by Merck & Co

    Find a price of 5-N,N-Dibenzylglycyl-Salicylamide bulk offered by Merck & Co

    Find a price of Arprinocid bulk offered by Merck & Co

    Find a price of Brompheniramine Maleate bulk offered by Merck & Co

    Find a price of Butorphanol Tartrate bulk offered by Merck & Co

    Find a price of CAS 50-28-2 bulk offered by Merck & Co

    Find a price of Chlorpheniramine Maleate bulk offered by Merck & Co

    Find a price of Conjugated Estrogens bulk offered by Merck & Co

    Find a price of Corticosterone bulk offered by Merck & Co

    Find a price of Danazol bulk offered by Merck & Co

    Find a price of Desogestrel bulk offered by Merck & Co

    Find a price of Dexamethasone bulk offered by Merck & Co

    Find a price of Dexamethasone Sodium Phosphate bulk offered by Merck & Co

    Find a price of Dexbrompheniramine Maleate bulk offered by Merck & Co

    Find a price of Dexchloropheniramine Maleate bulk offered by Merck & Co

    Find a price of Diethylstilbestrol bulk offered by Merck & Co

    Find a price of Diflunisal bulk offered by Merck & Co

    Find a price of Dihydrotestosterone bulk offered by Merck & Co

    Find a price of Diltiazem bulk offered by Merck & Co

    Find a price of Droperidol bulk offered by Merck & Co

    Find a price of Edrophonium Chloride bulk offered by Merck & Co

    Find a price of Enalapril Maleate bulk offered by Merck & Co

    Find a price of Estradiol bulk offered by Merck & Co

    Find a price of Estriol bulk offered by Merck & Co

    Find a price of Estrovarin bulk offered by Merck & Co

    Find a price of Ethinyl Estradiol bulk offered by Merck & Co

    Find a price of Fentanyl Citrate bulk offered by Merck & Co

    Find a price of Fluphenazine Decanoate bulk offered by Merck & Co

    Find a price of Heparin Sodium bulk offered by Merck & Co

    Find a price of Hyaluronic Acid bulk offered by Merck & Co

    Find a price of Imipramine Hydrochloride bulk offered by Merck & Co

    Find a price of Lovastatin bulk offered by Merck & Co

    Find a price of Medroxyprogesterone Acetate bulk offered by Merck & Co

    Find a price of Megestrol Acetate bulk offered by Merck & Co

    Find a price of Mestranol bulk offered by Merck & Co

    Find a price of Mk-6240 bulk offered by Merck & Co

    Find a price of Mk2048 bulk offered by Merck & Co

    Find a price of Nalbuphine Hydrochloride bulk offered by Merck & Co

    Find a price of Nalmefene Hydrochloride bulk offered by Merck & Co

    Find a price of Naltrexone bulk offered by Merck & Co

    Find a price of Neomycin Sulfate bulk offered by Merck & Co

    Find a price of Norandrostenedione bulk offered by Merck & Co

    Find a price of Norethisterone bulk offered by Merck & Co

    Find a price of Norethisterone Acetate bulk offered by Merck & Co

    Find a price of Norgestimate bulk offered by Merck & Co

    Find a price of Omeprazole Magnesium bulk offered by Merck & Co

    Find a price of Oxandrolone bulk offered by Merck & Co

    Find a price of Oxytocin bulk offered by Merck & Co

    Find a price of Pheniramine Maleate bulk offered by Merck & Co

    Find a price of Pimozide bulk offered by Merck & Co

    Find a price of Prasterone Acetate bulk offered by Merck & Co

    Find a price of Prednisolone Sodium Phosphate bulk offered by Merck & Co

    Find a price of Prochlorperazine Edisylate bulk offered by Merck & Co

    Find a price of Promethazine Hydrochloride bulk offered by Merck & Co

    Find a price of Pyridostigmine bulk offered by Merck & Co

    Find a price of Testosterone Propionate bulk offered by Merck & Co

    Find a price of Thiabendazole bulk offered by Merck & Co

    Find a price of Tibolone bulk offered by Merck & Co

    Find a price of Tubocurarine Chloride bulk offered by Merck & Co

    Find a price of Urofollitropin bulk offered by Merck & Co

    Find a price of Vitamin B12 bulk offered by Merck & Co

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN OKAZAKI CITY, JAPAN. bulk offered by Merck & Co

    Find a price of FACILS., METHODS & CONTROLS FOR PROCESSING & PACKAGING OF DRUG PRODS. bulk offered by Merck & Co

    Find a price of TECHNETIUM Tc 99M POLYPHOSPHATE KIT bulk offered by Merck & Co

    Find a price of PRO-STREP IN SWINE (VET) bulk offered by Merck & Co

    Find a price of MANUF&CONTROL FACILITIES&PROCEDURES AT SUBSIDIARY PLANT BARCELONETA,PR bulk offered by Merck & Co

    Find a price of MANUF. CONTROL FACILITIES & PROCEDURES FOR DANVILLE PA PLANT bulk offered by Merck & Co

    Find a price of PORCINE INSULIN HIGHLY PURIFIED bulk offered by Merck & Co

    Find a price of ORG 32489 RECOMBINANT FSH bulk offered by Merck & Co

    Find a price of AMPROL SUPER PLUS (AMPROLIUM & ETHOPABATE) (VET) bulk offered by Merck & Co

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN HOBBESDON, HERFORDSHIRE, ENGLAND. bulk offered by Merck & Co

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN WILSON, NORTH CAROLINA. bulk offered by Merck & Co

    Find a price of PREPARATION OF TEN STABLE ISOTOPE-LABELLED COMPOUNDS bulk offered by Merck & Co

    Find a price of FACILITIES AND OPERATING PROCEDURES IN CLERMONT-FERRAND,FRANCE bulk offered by Merck & Co

    Find a price of MK-4176 DRUG SUBSTANCE bulk offered by Merck & Co

    Find a price of NITROGEN MUSTARDS bulk offered by Merck & Co

    Find a price of AMPROLIUM IN CHICKENS (VET) bulk offered by Merck & Co

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES. bulk offered by Merck & Co

    Find a price of J-107088 bulk offered by Merck & Co

    Find a price of MANUF, CONTROL FACILITIES PROCEDURES FOR ALBANY, GA. PLANT bulk offered by Merck & Co

    Find a price of NORGESTOMET bulk offered by Merck & Co

    Find a price of AMPROLIUM MEDICATED FEED -(3-NITRO-4-HYDROXYPHENYLARSONIC ACID) (VET) bulk offered by Merck & Co

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN LE PUY CEDEX, FRANCE. bulk offered by Merck & Co

    Find a price of PRO-STREP CRUMBLES (VET) bulk offered by Merck & Co

    Find a price of HADACIDIN SOD. DIHYDRATE (NSC 521778) & HADACIDIN POTASS. NSC 72962 bulk offered by Merck & Co

    Find a price of RATHDRUM, COUNTY WICKLOW, IRELAND bulk offered by Merck & Co

    Find a price of HYDROCORT. 21-PHOSPHATE & NEOMYCIN SO4--OPTHAL. SOL. 0.5% & INJECT bulk offered by Merck & Co

    Find a price of MANUFACTURE AND CONTROL bulk offered by Merck & Co

    Find a price of CORTATE (DESOXYCORTICOSTERONE ACETATE) bulk offered by Merck & Co

    Find a price of PROCESS $ CONTROL DATE CONCERNING MANUFACTURE OF 2-ACETYLAMINA ETC. bulk offered by Merck & Co

    Find a price of L-000825058 bulk offered by Merck & Co

    Find a price of MANUF. & CONTROL,FACILITIES & PROCEDURES-FOR ELKTON, VA. PLANT bulk offered by Merck & Co

    Find a price of MANUF.CONTROL,FACILITIES &PROCEDURES-AT RAHWAY, NJ PLANT bulk offered by Merck & Co

    Find a price of STERILE DILUENT bulk offered by Merck & Co

    Find a price of L-651,392-00N,4-BROMO-2,7-DIMETHOXY-3H-PHENOTHIAZIN-3-ONE bulk offered by Merck & Co

    Find a price of FACILITY AND PROCEDURES IN OSS, THE NETHERLANDS - MOLENSTRAAT 110 bulk offered by Merck & Co

    Find a price of 1-METHYL-1-(B-CHLOROETHYL) ETHYLENIMONIUM PICRYSULFONATE bulk offered by Merck & Co

    Find a price of BULK FORM OF DRUG PRODUCT L-590,153 PROCESSED RAHWAY, N.J. FACILITIES bulk offered by Merck & Co

    Find a price of MERCK bulk offered by Merck & Co

    Find a price of Aprepitant bulk offered by Merck & Co

    Find a price of Avobenzona bulk offered by Merck & Co

    Find a price of Betamethasone Sodium Phosphate bulk offered by Merck & Co

    Find a price of Boceprevir bulk offered by Merck & Co

    Find a price of Boric Acid bulk offered by Merck & Co

    Find a price of CAS 532-40-1 bulk offered by Merck & Co

    Find a price of CAS 654671-77-9 bulk offered by Merck & Co

    Find a price of CAS 66376-36-1 bulk offered by Merck & Co

    Find a price of Caspofungin bulk offered by Merck & Co

    Find a price of Choriogonadotropin Alfa bulk offered by Merck & Co

    Find a price of Cilastatin bulk offered by Merck & Co

    Find a price of Cilastatin Sodium bulk offered by Merck & Co

    Find a price of Cocarboxylase bulk offered by Merck & Co

    Find a price of Cocarboxylase Tetrahydrate bulk offered by Merck & Co

    Find a price of Desloratadine bulk offered by Merck & Co

    Find a price of Doravirine bulk offered by Merck & Co

    Find a price of Elbasvir bulk offered by Merck & Co

    Find a price of Ensulizole bulk offered by Merck & Co

    Find a price of Ertapenem bulk offered by Merck & Co

    Find a price of Ezetimibe bulk offered by Merck & Co

    Find a price of Fenbendazole bulk offered by Merck & Co

    Find a price of Florfenicol bulk offered by Merck & Co

    Find a price of Flunixin Meglumine bulk offered by Merck & Co

    Find a price of Gentamicin Sulfate bulk offered by Merck & Co

    Find a price of Grazoprevir bulk offered by Merck & Co

    Find a price of Imipenem bulk offered by Merck & Co

    Find a price of Loratadine bulk offered by Merck & Co

    Find a price of Meglumine bulk offered by Merck & Co

    Find a price of Metformin bulk offered by Merck & Co

    Find a price of Milbemycin Oxime bulk offered by Merck & Co

    Find a price of Montelukast Sodium bulk offered by Merck & Co

    Find a price of Posaconazole bulk offered by Merck & Co

    Find a price of Potassium Phosphate bulk offered by Merck & Co

    Find a price of Raltegravir Potassium bulk offered by Merck & Co

    Find a price of Rocuronium Bromide bulk offered by Merck & Co

    Find a price of Simvastatin bulk offered by Merck & Co

    Find a price of Sitagliptin Phosphate bulk offered by Merck & Co

    Find a price of Sodium Fluoride bulk offered by Merck & Co

    Find a price of Suvorexant bulk offered by Merck & Co

    Find a price of Trisodium Citrate Dihydrate bulk offered by Merck & Co

    Find a price of Zinc Oxide bulk offered by Merck & Co

    Find a price of Lettermovir bulk offered by Merck & Co

    Find a price of LUPROSTIOL bulk offered by Merck & Co

    Find a price of MANUFACTURING OPERATIONS bulk offered by Merck & Co

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search